LDLR and hyperlipidemia: However, the evidence that everolimus, still caused hyperlipidemia in LDL receptor-null mice [38] suggest that a decrease in LDL-receptor expression is unlikely to be the only factor that contributes to hyperlipidemic effects seen in patients treated with mTOR inhibitors.